Work

Brentuximab Vedotin Plus Ibrutinib in Relapsed and Refractory Hodgkin Lymphoma

Year: 2024

Type: article

Study design: Clinical Trial

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2024.03.013

Authors: Matthew Mei, Ni-Chun Tsai, Joycelynne Palmer, Saro Armenian, Robert Chen, Steven Rosen, Stephen Forman, Leslie Popplewell, Larry Kwak, Peter Martin, Kami Maddocks, David Bond, Alex F. Herrera

Institutions: City Of Hope National Medical Center, City of Hope, NewYork–Presbyterian Hospital, Weill Cornell Medicine, The Ohio State University

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pharmacyclics

OpenAlex ID: W4394795393

FWCI: 0.261

Cites: 25

Cited by: 1

Related to: 10